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Abstract: Insulin-like growth factor-I (IGF-I) and insulin-like growth factor-II (IGF-II) play a crucial
factor in the growth, differentiation and survival of cells in health and disease. IGF-I and IGF-II
primarily activate the IGF-I receptor (IGF-IR), which is present on the cell surface. Activation of the
IGF-IR stimulates multiple pathways which finally results in multiple biological effects in a variety of
tissues and cells. In addition, activation of the IGF-IR has been found to be essential for the growth of
cancers. The conventional view in the past was that the IGF-IR was exclusively a tyrosine kinase
receptor and that phosphorylation of tyrosine residues, after binding of IGF-I to the IGF-IR, started a
cascade of post-receptor events. Recent research has shown that this view was too simplistic. It has
been found that the IGF-IR also has kinase-independent functions and may even emit signals in the
unoccupied state through some yet-to-be-defined non-canonical pathways. The IGF-IR may further
form hybrids with the insulin receptors but also with receptor tyrosine kinases (RTKs) outside the
insulin-IGF system. In addition, the IGF-IR has extensive cross-talk with many other receptor tyrosine
kinases and their downstream effectors. Moreover, there is now emerging evidence that the IGF-IR
utilizes parts of the G-protein coupled receptor (GPCR) pathways: the IGF-IR can be considered as
a functional RTK/GPCR hybrid, which integrates the kinase signaling with some IGF-IR mediated
canonical GPCR characteristics. Like the classical GPCRs the IGF-IR can also show homologous and
heterologous desensitization. Recently, it has been found that after activation by a ligand, the IGF-IR
may be translocated into the nucleus and function as a transcriptional cofactor. Thus, in recent years,
it has become clear that the IGF-IR signaling pathways are much more complex than first thought.
Therefore a big challenge for the (near) future will be how all the new knowledge about IGF-IR
signaling can be translated into the clinical practice and improve diagnosis and treatment of diseases.
Keywords: IGF-I; IGF-II; insulin; IGF-IR; IRs; tyrosine kinase receptor; GPCRs; hybrids;
phosphorylation; G-proteins; β-arrestins; functional RTK/GPCR hybrid; nuclear translocation
1. Introduction
The insulin-IGF system is formed by insulin, two insulin-like growth factors (IGF-I and IGF-II),
four cell-membrane receptors (insulin receptor-A (IR-A), insulin receptor-B (IR-B), insulin-like growth
factor-I receptor (IGF-IR) and insulin-like growth factor receptor-II (IGF-II-R)) and six IGF-binding
proteins (IGFBP-1-6), several IGFBP- related proteins and IGFBP proteases [1–4]. All IGFBPs can bind
both IGF-I and IGF-II (however with different binding affinity for some) [5]. Only the unbound forms
of IGFs are thought to interact with the IGF-IR and the IGF-II receptor [6].
The IGF-I gene comprises a highly conserved sequence and contains six exons, which give rise
to heterogeneous mRNA transcripts by a combination of multiple transcription initiation sites and
alternative splicing [7]. These multiple transcripts code in humans for different precursor IGF-I
polypeptides, namely the IGF-IEa, IGF-IEb and IGF-IEc isoforms, which also undergo posttranslational
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modifications, such as proteolytic processing and glycosylation [7]. Differential biological activities have
been reported for the different IGF-I isoforms and thus both common and unique or complementary
pathways exist for the IGF-I isoforms to promote biological effects [7].
As IGFs and insulin as well as the IGF-IR and the IRs share high sequence homology, they
are able to bind and activate each other’s cognate receptors but with considerably lower avidity.
The IGF-IR can bind IGF-I and IGF-II with equally high affinity (10−10 M) whereas its affinity
for insulin (10−8 M) is much lower [8]. In the past it was thought that the IGFs and the IGF-IR
predominantly mediated growth-promoting effects whereas insulin and the IRs predominantly
mediated metabolic effects [9,10]. However, in certain circumstances IGF-I and insulin can mediate
very similar responses [11]. Nevertheless, IGF-I and IGF-II play a crucial factor in the regulation of
growth, proliferation, differentiation, migration and survival of cells. In addition, activation of IGF-IR
and its intracellular pathways has been found to be essential for growth of cancers [12].
IGF-IIR regulates the amount of circulating and tissue IGF-II by transporting IGF-II into the cell
and degrading it [13]. IGF-II can also bind to the IGF-IR with high affinity [13].
Due to alternative splicing of exon 11 of the IR gene, two IR transcripts are generated in the human
body: IR-A (lacking exon 11) and IR-B (with exon 11) [14–16]. The IR-A is predominantly expressed in
fetal tissues, the central nervous system, hematopoietic cells and in cancer tissues [14]. The IR-B is
predominantly expressed in the liver, muscles and fat cells, the major target tissues for the metabolic
effects of insulin [14]. The binding of insulin to IR-B will mainly induce metabolic effects (glucose
uptake, glycogen synthesis, glycolysis and fatty acid synthesis) in liver, muscles and adipocytes [14].
Binding of insulin to the IR-A will predominantly induce growth-promoting effects in fetal tissues and
tumors. In contrast to IR-B, the IR-A may also bind IGF-II with high affinity and thereby stimulate
growth-promoting effects [14].
Although the liver is the main producer of the circulating IGFs, the IGFs are synthesized in almost
all tissues of the body [3].
The Insulin-like Growth Factor Binding Proteins (IGFBPs) are a family of six proteins with high
affinity for the IGFs. They are widely expressed in most tissues and are flexible endocrine and
autocrine/paracrine regulators of IGF activity, which is essential for this important physiological
system [3]. IGFBPs may affect cells in both an IGF-dependent and -independent manner [5]. Although
IGFBPs often inhibit IGF actions in many circumstances, in some conditions they may also potentiate
IGF actions [5].
2. IGF-I and the IGF-I Receptor
The IGF-IR is displayed on the cell surface and expressed by nearly all human tissues and cell
types [5,9,17]. Surface density of the IGF-IR represents an important determinant of the magnitude
of responses to IGF-I and the signaling pattern it provokes [18]. The IGF-IR is a heterotetrameric
transmembrane protein composed of two alpha and two beta subunits which are linked by disulfide
bonds [19,20]. The beta subunit of the IGF-IR consists of a short extracellular domain which is involved
in linkage to the alpha subunits, a transmembrane domain and a cytoplasmic domain containing
tyrosine kinase activity [21]. The beta subunit contains a consensus ATP-binding sequence and multiple
tyrosine residues that are phosphorylated following ligand binding to the alpha subunit [21]. Binding
of IGF-I or another ligand to the alpha subunit of the IGF-IR, induces a closer proximity of regions
within the transmembrane domain resulting in autophosphorylation of three intracellular tyrosine
residues (Tyr1131, Tyr1135, and Tyr1136) within the beta subunit [21–23].
The conventional view was that the IGF-IR was exclusively a tyrosine kinase receptor and that
the binding of IGF-I to the IGF-IR was essential to start the intracellular downstream signal cascade
(Figure 1). In this model, the activated receptor recruited and phosphorylated intracellularly substrates
as the insulin receptor substrate proteins (IRSs) and SH2 containing collagen-related proteins (SHC)
(Figure 1). Tyrosine phosphorylation of the IRSs in turn activated then the phosphatidylinositol
3-kinase (PI3K-Akt) pathway and its various biological responses, while tyrosine phosphorylation
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of SHC induced downstream signaling activation through the Ras/Raf/MEK/Erk pathway [24,25]
(Figure 1).
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Figure 1. The Insulin-like Growth Factor-I (IGF-IR) is a transmembrane protein composed of two 
alpha (α) and two beta (β) subunits. The conventional view was that the IGF-IR was exclusively a 
tyrosine kinase receptor and that the binding of IGF-I to the IGF-IR started the intracellular 
downstream signal cascade. In this model IGF-I or IGF-II binding to the IGF-IR promotes tyrosine 
kinase activity and autophosporylation of the beta subunit of the IGF-IR. Intracellularly the activated 
IGF-IR receptor recruits phosphorylated substrates Insulin receptor substrates (IRSs) and SH2 
containing collagen-related proteins (SHC). Tyrosine phosphorylation of IRSs and SHC proteins 
induces downstream signaling activation through the PI3K-AKT and Ras/Raf/MEK/Erk pathways. It 
was further thought that activation of the PI3K-AKT pathway had predominantly metabolic effects 
whereas activation of the Ras/Raf/MEK/Erk pathway had predominantly mitogenic effects. 
3. The IGF-IR and Endocytosis 
Many signaling receptors internalize via clathrin-coated pits [26]. Endocytosis of signaling 
receptors is widely recognized to confer control on cellular signaling responsiveness [27]. Ligand-
induced activation typically increases receptor endocytic rate, and internalized receptors engage 
molecular sorting machineries that specify subsequent transport via divergent lysosomal and 
recycling routes [27]. These events, in turn, determine the degree to which cellular ligand 
responsiveness is attenuated (“down-regulated”) or sustained (“re-sensitized”) under conditions of 
prolonged or repeated ligand exposure [27]. 
The molecular basis for the close interactions between IGF-IR endocytosis and its signaling 
components is still poorly understood. Recently, it has been suggested that the ability of insulin 
receptor substrate-1 (IRS-1) to interact with the clathrin adapter protein AP2, which is essential for 
endocytosis, plays an important role in IGF-IR internalization [28]. Overexpression of IRS-I resulted 
in the accumulation of activated IGF-IR at the cellular membrane [28]. Conversely, knockdown of 
IRS-I induced faster internalization of IGF-IRs [28]. These data suggest that IRS-1 inhibits the 
recruitment of IGF-IR into clathrin-coated structures; the ability of IRS-I to bind to AP-2 avoids rapid 
endocytosis of the IGF-IR and prolongs its activity at the cell surface in HEK293T cells [28] (Figure 
2A). In contrast, accelerating IGF-IR endocytosis via IRS-1 depletion induces the shift from sustained 
to transient Akt signaling [28] (Figure 2B). Thus, independent of its classic role as an adaptor in IGF-
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3. The IGF-IR and Endocytosis
Many signaling receptors internalize via clathrin-coated pits [26]. Endocytosis of signaling
receptors is widely recognized to confer control on cellular signaling responsiveness [27].
Ligand-induced activation typically increases receptor endocytic rate, and internalized receptors
engage molecular sorting machineries that specify subsequent transport via divergent lysosomal
and recycling routes [27]. These events, in turn, determine the degree to which cellular ligand
responsiveness is attenuated (“down-regulated”) or sustained (“re-sensitized”) under conditions of
prolonged or repeated ligand exposure [27].
The molecular basis for the close interactions between IGF-IR endocytosis and its signaling
components is still poorly understood. Recently, it has been suggested that the ability of insulin
receptor substrate-1 (IRS-1) to interact with the clathrin adapter protein AP2, which is essential for
endocytosis, plays an important role in IGF-IR internalization [28]. Overexpression of IRS-I resulted in
the accumulation of activated IGF-IR at the cellular membrane [28]. Conversely, knockdown of IRS-I
induced faster internalization of IGF-IRs [28]. These data suggest that IRS-1 inhibits the recruitment of
IGF-IR into clathrin-coated structures; the ability of IRS-I to bind to AP-2 avoids rapid endocytosis of
the IGF-IR and prolongs its activity at the cell surface in HEK293T cells [28] (Figure 2A). In contrast,
accelerating IGF-IR endocytosis via IRS-1 depletion induces the shift from sustained to transient Akt
signaling [28] (Figure 2B). Thus, independent of its classic role as an adaptor in IGF-I receptor signaling,
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IRS-1 has a role as an endocytic regulator of IGF-I receptor that ensures sustained IGF bioactivity, while
IRS-1 degradation could be a trigger to internalize the IGF-IR [29].
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Figure 2. Proposed role of Insulin receptor substrate-1 (IRS-1). IRS-1 modulates how long ligand-
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the cell IGF-IR endocytosis after the ligand stimulation is delayed. Mechanistically, IRS-1 inhibits the 
recruitment of IGF-IR into clathrin-coated structures; for this reason, IGF-IR avoids rapid endocytosis 
and prolongs its activity on the cell surface and this results in sustained activation of the AKT 
pathway. (B) In absence of IRS-1/AP2- complex in the cell, there is only short-term retention of the 
IGF-IR at the cell surface and IGF-IR endocytosis is accelerated. This results in a transient activation 
of the AKT pathway (Modified from Yoneyama et al. IRS-1 acts as an endocytic regulator of IGF-I 
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For the IGF-IR, ubiquitination also increases upon ligand binding [30]. The IGF-IR has been
demonstrated to be a substrate for three ubiquitin ligases: Mdm2, (in human malignant melanoma
cells), c-Cbl (HEK293 cells and human osteosarcoma cell lines U2OS and SAOS2) and Nedd4 (in mouse
embryo fibroblasts). [30,31]. Mdm2 was originally described to control IGF-IR ubiquitination and
thereby causing its degradation by the proteasome system [32]. Subsequently β-arrestins, known to
be involved in the regulation of G-protein-coupled receptors (GPCRs), have also been identified as
adaptor proteins to bring the oncoprotein Mdm2 to the IGF-IR in mouse embryo fibroblasts [33,34]. In
addition, while removing the IGF-IR from the cell surface and inhibiting the “classical” kinase signaling
pathway, β-arrestins may redirect the signaling wave through ERK [33] Ubiquitination may thus
induce receptor internalization and degradation, but also enhance IGF-IR signaling [35] (which will be
further addressed in the paragraph “the complexity of the post-receptor IGF-IR/IR pathways” below).
4. Structural Differences and Overlap between the IGF-IR and the IRs
It is hypothesized that the IGF-IR and IRs are created by gene duplication of common precursor
receptor molecule [36]. Due to structural and functional homology, IGF-I and insulin can bind to
(and activate) both IGF-IR and the IRs, as discussed above [37]. IGF-IR and IRs show 48% amino
acid sequence homology [20]. Structural differences between the beta-subunit and kinase domains
of the IGF-IR and the IRs leading to differences in substrate interactions may be (partly) responsible
for IGF-I and insulin specificity as has been found in various cell types (rat-1 fibroblasts, murine skin
keratinocytes and in NIH-3T3-fibroblasts) [38]. However, the signal transduction by the receptors may
not be limited to its activation at the cell surface [39].
In addition to signaling through the classical tyrosine kinase pathways, it has been found that the
IGF-IRs and IRs (in cells derived from C57Bl/6 mice) can emit signals in the unoccupied state through
some yet-to-be-defined non-canonical pathways [40]. Boucher et al. demonstrated that cells lacking the
IGF-IR and IR exhibit a major decrease in expression of multiple imprinted genes and microRNAs [40].
Although the IGF-IR and IRs have both distinct and overlapping functions, it has been suggested
that in vivo specificity of the IGFs and insulin are at least in part reflected by the timing of the expression
of the IGF-IR and IRs in target tissues in combination with ligand concentration and availability [41]. It
has been further suggested that IGF-I and the IRs act as identical portals for the regulation of gene
expression and that the differences between IGF-I and insulin effects are due to a modulation of the
amplitude of the signal created by the specific ligand receptor interaction [41].
5. The IGF-IR and the IRs May Form Hybrids in the Human Body
In cells and tissues where both significant levels of the IGF-IRs and IRs are present, hybrids
may be formed consisting of an alpha-beta subunit of the IGF-IR linked by disulfide bonds to an
alpha-beta subunit of the IR [42] (Figure 3A). They are formed in the endoplasmic reticulum before
they reach the cell surface [43]. Two splice variants of the hybrid receptors exist for the IR because the
IR is expressed (as above discussed) either with (IR-B) or without 12 amino acids encoded by exon 11
(IR-A) [44]. Thus both IR-A/IGF-IR (Hybrid A) and IR-B/IGF-IR (Hybrid B) receptors can be formed.
Although the biological functions of these hybrid receptors is still unclear, it has been suggested that
hybrid receptors may play a role in the overlapping functions of IGF-I and insulin [21]. Several studies
(in baby hamster kidney cells, NIH3T3 cells overexpressing IGFR and CHO cells overexpressing
IR-B) have suggested that cells by increasing the relative expression level of the IGF-IR above that
of the IR lose their insulin sensitivity because hybrid receptors bind insulin with low affinity [45,46].
In addition, binding of insulin to the alpha-beta subunit of the IR which is part of a hybrid, may result
in autophosphorylation of its ow beta subunit and, following transphosphorylation of the beta subunit
of the IGF-IR, may result in a signal for growth, [9]. In contrast, when IGF-I binds to the alpha-beta
subunit of the IGF-IR, this may activate the beta subunit of the IRs by the same mechanisms and
thereby activate growth (IR-A) or metabolism (IR-B) [9]. Although this latter mechanism could explain
why hybrids may stimulate metabolic functions when stimulated by IGF-I, most functional studies
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have found that hybrid receptors behave more like IGF-IRs than IRs [47]. It has been hypothesized that
this prioritization of hybrid receptors to IGF-I results from the ability of IGF-I to activate monomeric
IGF-IR whereas, in contrast, dimerization of the IR has been considered necessary to induce a response
to insulin [45].
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In cells and tissues where both significant levels of the IGF-IRs and IRs are present, hybrids
may be formed consisting of an alpha-beta subunit of the IGF-IR linked by disulfide bonds to an
alpha-beta subunit of the IR [42] (Figure 3A). They are formed in the endoplasmic reticulum before
they reach the cell surface [43]. Two splice variants of the hybrid receptors exist for the IR because the
IR is expressed (as above discussed) either with (IR-B) or without 12 amino acids encoded by exon 11
(IR-A) [44]. Thus both IR-A/IGF-IR (Hybrid A) and IR-B/IGF-IR (Hybrid B) receptors can be formed.
Although the biological functions of these hybrid receptors is still unclear, it has been suggested that
hybrid receptors may play a role in the overlapping functions of IGF-I and insulin [21]. Several studies
(in baby hamster kidney cells, NIH3T3 cells overexpressing IGFR and CHO cells overexpressing
IR-B) have suggested that cells by increasing the relative expression level of the IGF-IR above that
of the IR lose their insulin sensitivity because hybrid receptors bind insulin with low affinity [45,46].
In addition, binding of insulin to the alpha-beta subunit of the IR which is part of a hybrid, may result
in autophosphorylation of its ow beta subunit and, following transphosphorylation of the beta subunit
of the IGF-IR, may result in a signal for growth, [9]. In contrast, when IGF-I binds to the alpha-beta
subunit of the IGF-IR, this may activate the beta subunit of the IRs by the same mechanisms and
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thereby activate growth (IR-A) or metabolism (IR-B) [9]. Although this latter mechanism could explain
why hybrids may stimulate metabolic functions when stimulated by IGF-I, most functional studies
have found that hybrid receptors behave more like IGF-IRs than IRs [47]. It has been hypothesized that
this prioritization of hybrid receptors to IGF-I results from the ability of IGF-I to activate monomeric
IGF-IR whereas, in contrast, dimerization of the IR has been considered necessary to induce a response
to insulin [45].
It has been further hypothesized that IGF-IR/IR hybrids may affect tumor biology [48]. Specific
downregulation of the IGF-IR by agents solely targeting the IGF-IR diminishes hybrid formation and
this thereby enhances holo-IR formation [48]. An enhanced holo-IR formation results in an increase
of insulin sensitivity [48]. As the IR, especially the IR-A, may also activate (post-receptor) signaling
pathways involved in growth similar to the IGF-IR, the development of agents simultaneous targeting
both IR-A and IGF-IR may be necessary to disrupt the malignant phenotype of cancers cells that are
influenced by actions of the insulin-IGF system [48].
The IGF-IR may also heterodimerize with receptor tyrosine kinases (RTKs) outside the insulin-IGF
system [49]. Heterodimerization of the IGF-IR with the EGFR is well-established [50] (Figure 3B).
Downstream signaling of both receptors converge via the canonical PI3K-Akt and ERK signaling
pathways. Therefore inhibition of one receptor in these hybrids may shift the signaling pathway in
favor of the other available counterpart receptor [49,51,52]. Thus the compensatory signaling may be
bidirectional [53]. Moreover, evidence exists that IGF-IR can activate independently downstream EGFR
pathways and this may subsequently result in EFGR tyrosine kinase inhibitor (TKI) resistance [52].
The IGF-IR signaling pathway shows also cross-talk with the growth hormone receptor (GHR), thyroid
stimulating hormone receptor (TSHR) (Figure 3C), estrogen receptor (ER), androgen receptor (AR) and
human epidermal growth factor receptor 2 (HER-2) signaling pathways [54–59].
6. The Functional Relationship between Insulin/IGF Signaling and Discoidin Domain Receptors
In addition to its canonical role as a collagen receptor, it has recently been suggested that the
discoidin domain receptor-1 (DDR1), a tyrosine kinase receptor, plays an important role in the regulation
of the insulin-IGF system [60]. In contrast to most other RTKs, DDR1 is not activated by soluble growth
factors but instead by various type of collagens [60]. While most other RTKs are fully activated in
minutes, maximal activation of DDR1 occurs several hours after initial stimulation with collagen [60].
The DDR1 and the insulin-IGF system are linked by a feed-forward mechanism by which insulin and
the IGFs induce DDR1 upregulation which in turn enhances expression and activity of the IRs and
the IGF-IR [60]. The mechanisms by which DDR1 may affect downstream signaling of the IRs and
IGF-IR are as yet not fully understood. It has been found that increasing DDR1 expression favors the
expression of the more mitogenic IR-A isoform over the metabolic IR-B isoform and thus one of the
functional consequences of this DDR1 upregulation may be increased IGF-II signaling through the
IR-A [60]. This in turn may favor dedifferentiation and stem-like features [60]. It has been further
hypothesized that inhibition of DDR1 may be a way to downregulate the tumor-inducing actions of
the insulin/IGF system in human cancer cells while simultaneously inducing differentiation of cells
without affecting the IR-B mediated metabolic actions [60]. In favor of this latter hypothesis, in vitro
DDR1 silencing or downregulation blocked the IGF-2/IR-A autocrine loop in poorly differentiated
thyroid cancer cells and induced cellular differentiation [61]. Although at present no clinical studies
have shown that this strategy provides any clinical benefits for patients with tumors overexpressing the
DRR1 and the insulin-IGF-I system, these results may help to develop novel therapeutic approaches
for cancer.
7. The Complexity of the Post-Receptor IGF-IR/IR Pathways
In recent years, it has been become clear that the downstream complexity of the IGF-IR/IR
pathways was grossly underestimated in the past. In this section we will discuss some important
novel insights regarding this complexity. In the classical model, as discussed above, the IGF-IR was
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traditionally described as a tyrosine kinase receptor with an ON/OFF (active/inactive) system. In this
system IGF-I binding to the IGF-IR stabilized the ON state (active) and this exclusively mediated
kinase-dependent signaling activation of both the PI3-AKT and ERK pathways [62,63] (Figure 4A).
Ubiquitin-mediated receptor downregulation and degradation was originally described as a response
to ligand/receptor interaction and thus inseparable from kinase signaling activation [62].
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signaling was exclusively mediated by a kinase cascade through phosphorylation. The ligand-activate
IGF-IR was thought to lead to a balanced stimulation of the AKT/ERK pathways. (Abbreviation AKT=
protein kinase B; ERK= extracellular signal –regulated kinase) (B) In the current model, binding of a
ligand to the IGF-IR results not only in stimulating of the kinase cascade through phosphorylation
of IRS-1, PI3K and AKT but also in activation and signaling by G-proteins and β-arrestins, as well as
desensitization and internalization by β-arrestins. In this model ligand binding results in a balanced
activation and signaling of the kinase cascade, G-proteins and β-arrestins, as well as desensitization
and internalization by β-arrestins. (Modified from Girnita et al. Something old, something new
and something borrowed: emerging paradigm of insulin-like growth factor type 1 receptor (IGF-1R)
signaling regulation. Cell Mol Life Sci. 2014; 71:2403-27).
Almost 25 years ago, a study from Nobel Prize winner Dr. Robert Lefkowitz’s laboratory
reported that IGF-IR-dependent activation of the Mitogen-Activated Protein Kinase (MAPK) signaling
pathway was inhibited by the Gαi-inhibitor pertussis toxin [64]. The last years there is emerging
evidence that many RTKs can also utilize heterotetrameric G proteins to subserve some of their
biological actions [65–67]. Recently, more extensive evidence has been published that the IGF-IR
and IRs are also engaged in in G-protein coupled receptor (GPCR) signaling [62,63,65–67]. As GPCR
phosphorylation by GPCR-kinases (GRKs) governs interactions of the receptors with β-arrestins,
Zheng et al. investigated the regulatory roles of the four widely expressed GRKs on IGF-IR
signaling/degradation [68]. They found that lowering GRK5/6 abolished IGF-I-mediated ERK and
AKT activation, whereas GRK2 inhibition increased ERK activation and partially inhibited AKT
signaling [68]. In addition, β-arrestin-mediated ERK signaling was enhanced by overexpression of
GRK6 and diminished by GRK2. Similarly, they demonstrated opposing effects of GRK2 and -6 on
IGF-IR degradation: GRK2 decreased whereas GRK6 enhanced ligand-induced degradation [68].
GRK2 and GRK6 co-immunoprecipitated with IGF-IR and increased IGF-IR serine phosphorylation,
promoting β-arrestin1 association. Thus this study demonstrated distinct roles for GRK2 and GRK6 in
IGF-IR signaling through β-arrestin binding with divergent functional outcomes [68].
Based on the insight that IGF-IR may also “borrow” components of GPCR signaling, including
β-arrestins and G-protein-coupled-receptor kinases (GRKs), a new paradigm has emerged for the
IGF-IR [62]. In this new paradigm, the IGF-IR is considered to be a functional RTK/GPCR hybrid,
which integrates the kinase signaling with some IGF-IR mediated canonical GPCR characteristics [62].
Binding of IGF-I to the IGF-IR thus not only leads to balanced phosphorylation-dependent Akt/ERK
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signaling intracellularly, but results simultaneously also in activation of signaling by G-proteins and
β-arrestins [62] (Figures 4B and 5A).
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The IRs have been shown also to interact with G-proteins and β-arrestin-1 [69]. However, the
IGF-IR and IRs engage in different G-proteins for downstream signaling [65]. This possibly provides a
mechanism that is responsible for the signaling specificity of these two receptors [65].
Also another new paradigm, the paradigm of biased signaling, has been proposed for IGF-IR and
IR signaling [67,70]. The paradigm of biased signaling also originates from the GPCR signaling field [71].
The regulatory process which was discovered as the means by which classical GPCRs “desensitized“
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or tuned off, has been also found to be active for the IGF-IR [71]. In this paradigm the ligand is biased
towards a specific signaling i.e., the signal mediated by binding of a ligand to a receptor is no longer
balanced but the ligand elicits one response of the ligand over another compared with the classical
ligand [53,63]. The IGF-IR has been extensively studied as an anti-cancer target However, monotherapy
trials with IGF-IR targeted antibodies, have, overall, been very disappointing [12]. The anti-IGF-IR
antibody Figitumumab (CP-751,871; CP) was designed as an antagonist to prevent ligand-receptor
interaction [72]. Although it was found that CP blocked the kinase cascade pathway (by blocking
phosphorylation of IRS-1, PI3K and AKT), as with all anti-IGF-IR antibodies, it simultaneously induced
IGF-IR/β-arrestin-1 association with dual functional outcome: receptor ubiquitination and degradation
and decrease in cell viability and β-arrestin-1-dependent ERK signaling activation [72].
Thus despite blocking all the “classical” tyrosine kinase-mediated effects of the IGF-IR, a blocking
antibody directed against the IGF-IR may function as an IGF-IR/β-arrestin-1/ERK agonist and favor
β-arrestin-1/ERK signaling [73] (Figure 5B). Another example of biased signaling of the IGF-IR signaling
is mediated by LL-37, a newly recognized bacterial peptide, which after binding to the IGF-IR may
function as an IGF-IR agonist by increasing β-arrestin-1 signaling and electively activating the ERK
pathway but without affecting simultaneously the PI3K-AKT pathway [74].
One should make a distinction between homologous and heterologous desensitization.
Homologous desensitization occurs within a receptor system when it alters its own responsiveness,
for example the loss of responsiveness (desensitization) that can occur upon binding of insulin to
the IR [75]. It is considered to limit or restrain a cell’s responses to certain stimuli; it leaves a cell
(transiently) less- or unresponsive to a ligand that activates the desensitized receptor but not to ligands
that activate other receptors. In contrast, in heterologous desensitization the responsiveness of one
receptor system is regulated (positively or negatively) by activation of another receptor system (i.e.,
“cross-talk”) [75]. For example, insulin after binding to the IR may induce heterologous desensitization
of the signaling of the IGF-IR by downregulating β-arrestin-1 and inhibiting of IGF-I-stimulated MAP
kinase phosphorylation [76]. However, it has been found that this latter effect could be substantially
rescued by ectopic expression of wild-type β-arrestin-1, consistent with the view that the decrease in
cellular β-arrestin-1 content is a major mechanism for the observed desensitization effects of insulin on
IGF-IR mediated signaling [76].
8. The Nuclear Translocation of the IGF-IR and IRs and Its Significance
The IGF-IR and IRs not only function at the cell surface. When after binding of IGF-I to the IGF-IR
and the IGF-I/IGF-IR complex has been internalized into the cell, there are three potential outcomes for
the internalized IGF-IR: it can go back to the cellular surface, it can be degraded or it can go to the
nucleus [77].
It has been documented that both the IGF-IR and IRs can be translocated to the nucleus [78,79].
Nuclear transport of IGF-IR is enhanced by IGF-I and IGF-II but only modestly by insulin [79]. This
transport correlated directly with the magnitude of ligand-induced receptor phosphorylation of the
IGF-IR with these ligands [79]. In addition, it has been found that ligand-mediated phosphorylation of
the IGF-IR is essential for nuclear trafficking [78].
IGF-IR nuclear import and chromatin binding can be blocked by an IGF-IR kinase inhibitor,
indicating that indeed IGF-IR kinase activity is required for the IGF-IR to enter the nucleus [79].
The IGF-IR can undergo both caveolin- and clathrin mediated endocytosis [80,81]. Consistent
with clathrin-mediated endocytosis, nuclear IGF-IR translocation can be blocked by the inhibitors of
clathrin-dependent endocytosis (dansylcadaverine and the dynamin-1 inhibitor dynasore), but not
by caveolin-1 depletion [79]. Nevertheless, the exact mechanisms responsible for nuclear import of
the IGF-IR and IRs are still unclear [78]. Sehat et al. found that the α subunit (native size, 120 kD)
together with the β subunit (native size, 95 kD) was present in the nuclear fraction, suggesting that
nuclear IGF-IR was an intact receptor [82]. Data of Aleksic et al. also suggested that full-length IGF-IR
translocates to the nucleus [79].
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Both the IGF-IR and IRs are present in the perinuclear and nucleolar area of the nucleus in a small
ubiquitin-like modifier SUMOylated form [78]. Receptor SUMOylation occurs in a ligand dependent
fashion and it has been demonstrated that SUMOylation plays a crucial role in the nuclear translocation
of the IGF-IR [82,83] (Figure 6). The SUMO-modified IGF-IR is deSUMOylated after passage across the
nuclear membrane [82]. Nuclear IGF-IR binds to enhancer regions and activates transcription [84]. It is
able to autoregulate expression of its own gene leading to an increase in IGF-IR promoter activity and
IGF-IR expression [78] (Figure 6).
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Figure 6. Studies have confirmed that ligand-mediated phosphorylation of the IGF-IR is essential for
nuclear trafficking. Following binding of IGF-I to the IGF-IR at the cell surface, the IGF-IR is transported
into the cell and further translocated from the cytoplasm into the nucleus. SUMOylation (SUMO-1) in
the cytoplasm of the IGF-IR also plays a crucial role in the nuclear translocation of the IGF-IR from
the cytoplasm. When the SUMOylated IGF-IR translocates to the nucleus, it is thought to be involved
in the transcriptional enhancement of specific target genes. Nuclear IGF-IR is able to autoregulate
expression of its own gene leading to an increase in IGF-IR promoter activity and IGF-IR expression
(left). Nuclear IGF-IR may also bind to Cyclin D1 (and additional) promoters with ensuing target gene
activation (right). (Modified from Sarfstein & Werner. Minireview: nuclear insulin and insulin-like
growth factor-1 receptors: a novel paradigm in signal transduction. Endocrinology, 2013; 154:1672-9).
It has been further suggested that nuclear IGF-IR has biological significance in cancer; prognosis
was less good and survival was shorter in patients whose tumor showed intense and/or widespread
nuclear IGF-IR [79]. It has been reported that nuclear IGF-IR is a feature of pre-invasive lesions and
invasive cancers including prostate, renal and breast cancers, and an association between nuclear IGF-IR
and adverse prognosis was identified in renal cancer [79]. Subsequent data did associate nuclear IGF-IR
with proliferation, tumorigenicity, resistance to EGFR inhibition and clinical response to therapeutic
anti-IGF-IR antibodies, which suggests that IGF-IR nuclear import has biological significance and may
contribute directly to IGF-IR function [79,85–90].
When the IGF-IR translocates to the nucleus, it is thought to be involved in the transcriptional
enhancement of specific target genes [79,82,91]. It has been demonstrated that IGF-IR in the nucleus
binds to the transcription factor lymphoid enhancer factor-1 (LEF1), leading to elevated protein levels
of cyclin D1 and axin2 [84] (Figure 6). This might be an additional molecular mechanism by which
IGF-IR promotes uncontrolled cell proliferation and contribute to the neoplastic transformation of
cells [84].
When investigating the impact of IGF-IR levels on IGF-IR biosynthesis in estrogen receptor
positive (ER+) and estrogen receptor depleted (ER-) breast cancer cells, it was found that in ER+ cell
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and ER- cells regulation of the IGF-IR gene and IGF-IR protein differed at the level of transcription;
the IGF-IR protein was able to stimulate IGF-IR gene expression in ER- cells but not in ER+ cells [92].
Similarly to the IGF-IR, it was found that the IR was also translocated to the nucleus and to bind to the
IGF-IR promoter. However, this was only observed in ER- cells but not in ER+ cells [92].
In addition, it has been found that transcription factors IGF-IR and IR display diametrically
opposite activities in the context of IGF-IR gene regulation; in contrast to the IGF-IR, IR inhibited IGF-IR
promoter activity [92]. Thus nuclear IGF-IR acted as a transcriptional activator of its own promoter,
while nuclear IR functioned as a negative regulator of IGF-IR promoter activity [92]. Nevertheless, the
authors of this latter paper concluded that the clinical implications of their findings—in particular
the impact of IGF-IR/IR nuclear localization on targeted therapy—are at present unclear and require
further investigation [92].
9. Conclusions
Although until recently the conventional view was that phosphorylation of tyrosine residues
played a major role in the activation of the IGF-IR and initiated all downstream signaling, there
is increasing evidence showing that this view was too simplistic and grossly underestimated the
downstream complexity of the IGF-IR pathways. The IGF-IR has not only extensive cross-talk with
many other receptors, but that the IGF-IR can be also considered as a functional RTK/GPCR hybrid,
which integrates the kinase signaling with some IGF-IR mediated canonical GPCR characteristics.
Like classical GPCRs the IGF-IR show homologous and heterologous desensitization. In addition,
after activation by a ligand, the IGF-IR signaling can be translocated to the nucleus and function as a
transcriptional cofactor. For example nuclear IGF-IR is able to autoregulate expression of its own gene.
Thus, it has become clear in recent years that the IGF-IR signaling pathway is far more complex
than previously thought. It contains many points of regulation and shows signal divergence and
cross-talk with many other signaling pathways at the receptor and post-receptor level. However, a
big challenge for the (near) future will be how all this new knowledge about the IGF-IR signaling
pathways can be translated into clinical practice and improve diagnosis and treatment of diseases.
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